Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Metformin
Bamlanivimab Molnupiravir
Bromhexine Nigella Sativa
Budesonide Nitazoxanide
Casirivimab/i.. Povidone-Iod..
Colchicine Probiotics
Conv. Plasma Proxalutamide
Curcumin Quercetin
Favipiravir Remdesivir
Fluvoxamine Sotrovimab
Hydroxychloro.. Vitamin A
Iota-carragee.. Vitamin C
Ivermectin Vitamin D
Melatonin Zinc

Other Adoption
Colchicine study #12 of 12   All Outcomes
9/23 Late treatment study
Dorward et al., medRxiv, doi:2021.09.20.21263828 (Preprint)
Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
Source   PDF   Share   Tweet
Late treatment RCT with 156 colchicine patients in the UK, showing no significant differences. ISRCTN86534580.
Dorward et al., 9/23/2021, Randomized Controlled Trial, United Kingdom, Europe, preprint, 21 authors.
risk of combined hospitalization/death, 29.8% higher, RR 1.30, p = 0.65, treatment 6 of 156 (3.8%), control 4 of 133 (3.0%), odds ratio converted to relative risk, concurrent randomisation.
risk of combined hospitalization/death, 22.1% lower, RR 0.78, p = 0.55, treatment 6 of 156 (3.8%), control 119 of 1145 (10.4%), odds ratio converted to relative risk, including control patients before the colchicine arm started.
risk of disease progression, 6.0% lower, RR 0.94, p = 0.45, treatment 102 of 156 (65.4%), control 83 of 120 (69.2%).
risk of no recovery, 6.0% lower, RR 0.94, p = 0.67, treatment 156, control 133, time to alleviation of symptoms.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
All 12 studies   All Outcomes
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Submit